Celltrion Will Market Subcutaneous Remsima Directly After EU Nod

 
• By Dave Wallace and Jung Won Shin

Celltrion has set out plans to market directly its subcutaneous version of infliximab in Europe. The firm has just received a nod that sets the stage for approval across the EU, albeit with more limited indications than the existing intravenous version.

EMA
The EMA’s CHMP has endorsed Celltrion’s subcutaneous infliximab • Source: Shutterstock

More from Strategy

More from Business